Healthcare
Live Price
Offline$2.02
+0.00% today
1Y Change
+3.32%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) is a Healthcare stock with a market cap of $65.69B and listed on OTC. The stock last traded around $2.02 and up 3.3% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -1.6%, EPS growth of +21.2%, a dividend yield of 1.3%. What stands out right now is revenue -1.6%, EPS +21.2%, free cash flow +1045.0% with operating margin 9.6% and ROIC 3.1%. The dividend is present but secondary, with a yield around 1.3%. Valuation is more restrained than many high-expectation growth names at P/E 18.9 and price/sales 1.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SFOSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SFOSF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SFOSF Max Drawdown
-42.29%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SFOSF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$39.0B
-11.3% YoY
FY Net Income
$4.7B
+26.7% YoY
Free Cash Flow
-$1.0B
+38.7% YoY
Revenue Growth
-1.6%
EPS Growth
+21.2%
Gross Margin
49.4%
Net Margin
8.2%
Income statement
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 40.4B | 41.1B | 41.4B | 44.0B | 39.0B |
| Gross Profit | 20.2B | 19.7B | 19.8B | 20.8B | 18.8B |
| Operating Income | 2.5B | 4.2B | 3.3B | 8.3B | 6.3B |
| EBITDA | 6.2B | 8.6B | 5.6B | 7.9B | 8.8B |
| Net Income | 3.3B | 2.8B | 2.4B | 3.7B | 4.7B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 13.1B | 13.5B | 13.7B | 16.2B | 10.3B |
| Total Assets | 120.1B | 117.5B | 113.5B | 107.2B | 93.3B |
| Total Liabilities | 58.2B | 57.5B | 56.9B | 53.1B | 44.9B |
| Shareholder Equity | 48.7B | 47.3B | 45.7B | 44.6B | 39.2B |
| Total Debt | 36.7B | 31.7B | 30.3B | 30.2B | 24.2B |
| Net Debt | 23.5B | 18.2B | 16.6B | 14.0B | 13.9B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3.9B
-6.4% YoY
Capital Expenditures
5.0B
+15.6% YoY
Free Cash Flow
1.0B
+38.7% YoY
Key ratios
Gross Margin
49.4%
Operating Margin
9.6%
Net Margin
8.2%
ROE
7.2%
Debt / Equity
0.81x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.